Johnathan Goodwin, MD
Gastroenterology · North Little Rock, ARNPI 1295963379
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,276 of the $5,051 with a category attached, or 84.7%. 21 manufacturers reported payments, led by AbbVie at 41.6% of the total.
Across 299 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Braintree Laboratories, Inc.$776
- Johnson & Johnson$519
- Pfizer$328
- Takeda Pharmaceuticals U.S.A., Inc.$245
- Janssen Scientific Affairs, LLC$218
- plus $864 from 15 others
Across 62 payments — averaging $9112.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$532K
- Phathom Pharmaceuticals, Inc.$23K
- Ardelyx, Inc.$10K
What the payments were for
- Food & beverage$4,27685%
- Education$471%
- Gifts$72814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 161 | $2,101 |
| Braintree Laboratories, Inc. | 25 | $776 |
| Johnson & Johnson | 32 | $519 |
| Pfizer | 19 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $245 |
| Janssen Scientific Affairs, LLC | 3 | $218 |
| Regeneron Healthcare Solutions, Inc. | 6 | $195 |
| Merck | 7 | $124 |
| Aimmune Therapeutics, Inc. | 5 | $102 |
| Sanofi | 4 | $101 |
| Gilead | 4 | $71 |
| Medtronic | 1 | $46 |
| Redhill Biopharma Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $38 |
| Evoke Pharma, Inc. | 2 | $34 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 4 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ardelyx, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$113
How this compares
$5,051 in reported general payments places this provider in the 55th percentile of 108 gastroenterology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $612,930 |
| Xeljanz XrTofacitinib Citrate | 12 | $69,763 |
| LinzessLinaclotide | 69 | $46,037 |
| CreonLipase/Protease/Amylase | 11 | $18,566 |
| Colestipol Hcl | 155 | $9,128 |
| Budesonide DrBudesonide | 35 | $7,964 |
| Pantoprazole Sodium | 718 | $6,364 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 35 | $5,663 |
| Mesalamine | 17 | $4,848 |
| Omeprazole | 509 | $4,819 |
| Lubiprostone | 46 | $3,695 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 48 | $3,077 |
| Ursodiol | 25 | $2,866 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 19 | $2,333 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 148 | $2,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $519 | $612,93023 claims |
| AbbVieLinzess, Creon | $2,101 | $64,60280 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $776 | $7,99654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 gastroenterology providers in Arkansas.
Other gastroenterology in North Little Rock
- Patrick SelakovichNorth Little Rock$6K
- Scott WoffordNorth Little Rock$6K
- Whitfield KnappleNorth Little Rock$5K
- Samuel DunnNorth Little Rock$3K
- Glenn DavisLittle Rock$2.7M
- Ranga BalasekaranSpringdale$235K
- Ali KhanLittle Rock$49K
- Jaymie PenningtonLittle Rock$17K
- Michael JohnsonLittle Rock$17K
- David BackstedtLittle Rock$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.